Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

医学 伦瓦提尼 彭布罗利珠单抗 内科学 肿瘤科 子宫内膜癌 卡铂 化疗 癌症 免疫疗法 甲状腺癌 顺铂
作者
Christian Marth,Rafał Tarnawski,Alexandra Tyulyandina,Sandro Pignata,Lucy Gilbert,Diego Kaen,María Jesús Rubio,Sophia Frentzas,Mario Beiner,Manuel Magallanes-Maciel,Laura Farrelly,Chel Hun Choi,Regina Berger,Christine Lee,Christof Vulsteke,Kosei Hasegawa,Elena Ioana Braicu,Xiaohua Wu,Jodi A. McKenzie,John J. Lee,Vicky Makker
出处
期刊:International Journal of Gynecological Cancer [BMJ]
卷期号:32 (1): 93-100 被引量:36
标识
DOI:10.1136/ijgc-2021-003017
摘要

Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) after ≤2 previous lines of therapy. In a randomized phase 3 trial of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (KEYNOTE-775/Study 309), after 1‒2 previous lines of therapy (including neoadjuvant/adjuvant), this combination improved objective response rates, progression-free survival, and overall survival compared with chemotherapy.To compare the efficacy and safety of first-line pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin in patients with newly diagnosed stage III/IV or recurrent endometrial cancer, with measurable or radiographically apparent disease.Pembrolizumab plus lenvatinib is superior to chemotherapy with respect to progression-free survival and overall survival in patients with mismatch repair-proficient tumors and all patients (all-comers).Phase 3, randomized (1:1), open-label, active-controlled trial. Patients will receive pembrolizumab intravenously every 3 weeks plus lenvatinib orally daily or paclitaxel plus carboplatin intravenously every 3 weeks, stratified by mismatch repair status (proficient vs deficient). Patients with mismatch repair-proficient tumors will be further stratified by Eastern Cooperative Oncology Group performance status (0/1), measurable disease (yes/no), and prior chemotherapy and/or chemoradiation (yes/no).Adults with stage III/IV/recurrent histologically confirmed endometrial cancer that is measurable or radiographically apparent per blinded independent central review. Patients may have received previous chemotherapy only as neoadjuvant/adjuvant therapy and/or concurrently with radiation. Patients with carcinosarcoma (malignant mixed Müllerian tumor), endometrial leiomyosarcoma, or other high grade sarcomas, or endometrial stromal sarcomas were excluded.Progression-free and overall survival (dual primary endpoints).About 875 patients.Enrollment is expected to take approximately 24 months, with presentation of results in 2022.ClinicalTrials.gov, NCT03884101.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
J_完成签到,获得积分10
刚刚
wahfiaeghi完成签到,获得积分10
刚刚
刚刚
1秒前
无花果的应助被Yahooo采纳,获得10
1秒前
ali完成签到,获得积分10
2秒前
sy完成签到 ,获得积分10
2秒前
3秒前
wuly发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
小叮当发布了新的文献求助10
4秒前
原儿完成签到,获得积分10
4秒前
大力的纸鹤完成签到,获得积分10
4秒前
4秒前
学术雷锋发布了新的文献求助10
5秒前
菜菜包完成签到,获得积分10
5秒前
呼延忘幽发布了新的文献求助10
6秒前
忐忑的子骞完成签到,获得积分10
6秒前
浮生完成签到,获得积分10
6秒前
7秒前
7秒前
天地一沙鸥完成签到,获得积分10
7秒前
Aurora发布了新的文献求助20
7秒前
pipizhu完成签到,获得积分10
8秒前
小鱼爱吃肉的应助被愉快翩跹采纳,获得10
8秒前
肆_完成签到 ,获得积分10
8秒前
郑璇完成签到,获得积分10
10秒前
10秒前
10秒前
咯咯哒发布了新的文献求助10
11秒前
共享精神的应助被欣慰的嘉熙采纳,获得10
11秒前
11秒前
传奇3的应助被lyy采纳,获得10
12秒前
fire发布了新的文献求助30
12秒前
Lll发布了新的文献求助10
12秒前
重要惜雪完成签到 ,获得积分10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161319
求助须知:如何正确求助?哪些是违规求助? 9556017
关于积分的说明 21731933
捐赠科研通 7751355
什么是DOI,文献DOI怎么找? 3427537
关于科研通互助平台的介绍 2552583
邀请新用户注册赠送积分活动 2471987